Sort
146,196 grants matching “diabetes”
Regional Prospective Observational Research in Tuberculosis (RePORT) â Brazil Network
$1,000,000Timothy R Sterling · Vanderbilt University Medical Center · U01 · FY2025 · AI
Clinical Center for Look AHEAD: Health in Diabetes
$1,000,000University Of Pennsylvania · U01 · FY2001 · DK
Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device
$1,000,000Richard Saul · Mellitus, Llc · R44 · FY2021 · DK
HISPANIC COMMUNITY HEALTH STUDY-STUDY OF LATINOS (HCHS-SOL)- COORDINATING CENTER
$1,000,000Jianwen Cai · Univ Of North Carolina Chapel Hill · N01 · FY2024 · HL
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2024 · DK
Continuation of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Data Coordinating Center
$999,999Robert M Merion · Arbor Research Collaborative For Health · U24 · FY2020 · DK
Augmenting the CMDKP with advanced features for understanding biological mechanisms
$999,999Jason Flannick · Broad Institute, Inc. · UM1 · FY2025 · DK
Continuation of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Data Coordinating Center
$999,999Robert M Merion · Arbor Research Collaborative For Health · U24 · FY2019 · DK
STUDY TO ASSESS THE INCIDENCE OF TYPE 1 DIABETES IN YOUNG ADULTS
$999,999Jean Marie Lawrence · Kaiser Foundation Research Institute · U18 · FY2016 · DP
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2023 · DK
Data Coordinating Center for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Continuation
$999,999David M Shade · Johns Hopkins University · U24 · FY2025 · DK
A Bullet Proof vascular graft to prevent dialysis access cannulation injury
$999,998Joseph Knight · Innavasc Medical, Inc. · R44 · FY2022 · DK
Expanding Vietnamese Community and Academic Infrastructure for Health Research
$999,998Bang H Nguyen · Cancer Prevention Instit Of California · RC4 · FY2010 · MD
Mid Southern Primary Care Networks Node
$999,998Li-Tzy T Wu · Duke University · UG1 · FY2019 · DA
Enabling improved applicability and transferability of polygenic scores across diverse populations- a focus on South Asians
$999,998Pradeep Natarajan · Massachusetts General Hospital · U01 · FY2021 · HG
Yale Cooperative Hematology Specialized Core Center
$999,996Diane S. Krause · Yale University · U54 · FY2015 · DK
Humanized monoclonal antibodies to treat mucormycosis
$999,975Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2024 · AI
DP24-004, PRC: Core, University of Pittsburgh Health Promotion and Disease Prevention Research Center
$999,972Shari S Rogal · University Of Pittsburgh At Pittsburgh · U48 · FY2025 · DP
GENHAT-GENETICS OF HYPERTENSION ASSOCIATED TREATMENTS
$999,971University Of Alabama At Birmingham · R01 · FY2003 · HL
Component A: A multi-level study of community context and type 2 diabetes and coronary heart disease using electronic health record and new primary data across nested geographies in Pennsylvania
$999,966Annemarie Gregory Hirsch · Geisinger Clinic · U01 · FY2020 · DP
First-In-Human Feasibility Trial of Break Wave - The Office-Based Lithotripsy Solution
$999,958Oren Levy · Sonomotion, Inc. · R44 · FY2019 · DK
A microbial engineering platform for sustainable, scalable, and cost-effective production of pharmaceutical grade cannabinoids and related compounds
$999,954Spiros Kambourakis · Cellibre Inc · R44 · FY2024 · AT
A microbial engineering platform for sustainable, scalable, and cost-effective production of pharmaceutical grade cannabinoids and related compounds
$999,954Spiros Kambourakis · Cellibre Inc · R44 · FY2025 · AT
A PROSPECTIVE STUDY OF ALASKA NATIVES &AMERICAN INDIANS
$999,952University Of Utah · R01 · FY2002 · CA
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists
$999,917Richard Scott Struthers · Crinetics Pharmaceuticals, Inc. · R44 · FY2013 · DK